Summary
This study is researching an experimental drug called fianlimab (also called REGN3767),
combined with a medication called cemiplimab compared against cemiplimab combined with
placebo (a placebo looks like a treatment but does not contain any real medicine),
collectively called "study drugs" in this form.
The study is focused on participants with head and neck cancers who have not been
previously treated for head and neck cancer that has come back or spread to other parts
of the body, referred to as recurrent or metastatic (R/M) head and neck squamous cell
carcinoma (HNSCC).
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drugs
- How much of each study drug is in the blood at different times
- Whether the body makes antibodies against the study drug(s) individually (which
could make the study drugs less effective or could lead to side effects)
- Compatible research to better understand the study drugs and HNSCC